Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'.

about

Role of circulating tumor DNA in the management of early-stage lung cancer.

P2860

Q54340242-B283E58E-A625-4166-9769-B7A1FA67640A

P2860

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'.

Item

http://www.wikidata.org/entity/Q40169633

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Predicting lung cancer recurre ...... -stage lung cancer evolution'.

@en

type

Item

label

Predicting lung cancer recurre ...... -stage lung cancer evolution'.

@en

prefLabel

Predicting lung cancer recurre ...... -stage lung cancer evolution'.

@en

P1476

Predicting lung cancer recurre ...... -stage lung cancer evolution'.

@en

P2860

Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Tracking genomic cancer evolution for precision medicine: the lung TRACERx study

Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer?

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Minimal-dose computed tomography is superior to chest x-ray for the follow-up and treatment of patients with resected lung cancer.

P2888

cdd.2017.97

P304

1473-1474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CDD.2017.97

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniel J Murphy

Kevin G Blyth

P577

2017-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1086040154

http://www.w3.org/2001/XMLSchema#string

P698

28622291

http://www.w3.org/2001/XMLSchema#string

P921

phylogenetics

P932

5563996

http://www.w3.org/2001/XMLSchema#string

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'.

about

P2860

P2860

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932